Destiny Pharma
Skip to content
  • Home
  • Company
    • Our Focus
    • Board of Directors
    • Scientific Advisory Board
    • Business Development
    • Vision
  • Need
    • Antibiotic Resistance
    • Post Surgical Infections
    • Incentives for New Antibacterial Drugs
    • Societal Cost
    • Links
  • Platform
    • XF Drug Series
    • XF-73 (exeporfinium chloride)
    • Pipeline
  • Market
  • Investors
    • AIM Rule 26
    • Share Price
    • Regulatory News
    • Company Information
    • Documents
    • Reports & Presentations
    • Advisers
    • Analyst Coverage
    • Corporate Governance
  • News
    • Regulatory news – News
  • Contact
    • Careers
News & Events

Revolutionary Superbug Treatment

 

Continue Reading

Neil Clark, CEO, interviewed at Proactive Investor event on 28 January 2019

Posted on 30/01/2019 by Kirsty Richardson

Please follow link below to watch Proactive Investor interview:

Neil Clark, CEO, interviewed at Proactive Investor event on 28 January 2019

Categories : News
Bookmark the permalink

Post navigation

Previous PostSecond positive Phase 1 trial data for XF-73
Next PostDestiny Pharma to attend BIO-Europe Spring, 25 – 27 March 2019, Vienna, Austria

Categories

  • Categories
    • Events
    • News
    • Press Release
    • Uncategorised

    • Archives

    • Archives

    Destiny Pharma

    © All rights reserved.

    Powered by WordPress

    Destiny Pharma plc
    Sussex Innovation Centre
    Science Park Square
    Falmer
    Brighton
    BN1 9SB
    UK

    Tel: +44(0) 1273 704440

    Registered Company
    No. 3167025
    Home
    Company
    Need
    Platform
    Market
    Investors
    News
    Contact
    Terms of Use